From the Guidelines
Yes, covering a urinary tract infection with both Pseudomonas aeruginosa and Enterococcus faecalis using Zosyn (piperacillin-tazobactam) and ampicillin is appropriate, as it provides comprehensive coverage against both pathogens. According to the most recent guidelines 1, for urinary tract infections involving Pseudomonas, piperacillin-tazobactam is a recommended treatment option. For Enterococcus faecalis, ampicillin is a suitable choice, as seen in guidelines for treating enterococcal infections 2.
Treatment Details
- Zosyn (piperacillin-tazobactam) can be dosed at 3.375g IV every 6 hours (or 4.5g every 6 hours in severe infections) to cover Pseudomonas aeruginosa, as per recommendations for treating infections due to multidrug-resistant organisms 1.
- Ampicillin can be given at 1-2g IV every 6 hours to target Enterococcus faecalis, considering its efficacy against this pathogen 2.
- Both medications should be adjusted for renal function if needed, to minimize the risk of toxicity and ensure optimal drug levels.
- This combination therapy is necessary because Pseudomonas is intrinsically resistant to ampicillin, and while Zosyn has some enterococcal activity, dedicated enterococcal coverage with ampicillin provides more reliable treatment.
Monitoring and Duration
- Once susceptibility results are available, therapy can potentially be narrowed to more targeted treatments.
- Treatment duration typically ranges from 7-14 days depending on clinical response and complicating factors, as suggested by guidelines for managing infections 1.
- Adequate hydration should be maintained throughout treatment, and clinical improvement should be monitored with follow-up urine cultures if symptoms persist, to ensure the infection is fully cleared and to adjust treatment as necessary.
From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Treatment of Pseudomonas and Enterococcus faecalis Infections
- The use of piperacillin-tazobactam has been studied as a treatment for Pseudomonas aeruginosa infections, with extended-infusion dosing strategies showing improved clinical outcomes 3.
- For Enterococcus faecalis, piperacillin-tazobactam may be an effective alternative to carbapenems for the treatment of nonbacteremic urinary tract infections, although the evidence is not conclusive 4.
- The bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against Enterococcus faecalis and Pseudomonas aeruginosa have been compared, with all regimens demonstrating good activity against Bacteroides fragilis and Escherichia coli, but limited activity against E. faecalis and P. aeruginosa 5.
- Enterococcus faecalis has been shown to antagonize Pseudomonas aeruginosa growth in mixed-species interactions, particularly under iron-restricted conditions, by decreasing environmental pH and l-lactate-mediated iron chelation 6.
- Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa include exposure to piperacillin-tazobactam, imipenem, aminoglycosides, vancomycin, and broad-spectrum cephalosporins 7.
Coverage with Zosyn and Ampicillin
- Based on the available evidence, covering Pseudomonas and Enterococcus faecalis with Zosyn (piperacillin-tazobactam) and ampicillin may be appropriate, considering the bactericidal activities of these antibiotics against these organisms 5.
- However, the use of ampicillin-sulbactam has been associated with the recovery of piperacillin-tazobactam-susceptible P. aeruginosa, suggesting that this combination may not be the most effective choice for treating Pseudomonas infections 7.
- The decision to use Zosyn and ampicillin should be based on the specific clinical context and the susceptibility patterns of the isolated organisms.